You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Production of High Specific Activity Lutetium-177

    SBC: ALPHAMED, INC            Topic: N/A

    DESCRIPTION (provided by applicant): A separation method will be tested and evaluated to determine the feasibility of providing no carrier added lutetium-177 (Lu-177) for use in radiotherapeutic applications. An indirect method will be used to produce Lu-177 (neutron capture followed by decay). Separation of the Lu-177 from the target material will enable us to provide carrier-free Lu-177 suita ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  2. Histone Deacetylase Inhibitors for Cancer Treatment

    SBC: Angiogen, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Histone deacetylases (HDACs) comprise a family of enzymes that catalyze the removal of acetyl groups from lysine residues of histones. They mediate chromatin remodeling and gene expression. HDAC inhibitors are potent inducers of growth arrest, differentiation or apoptic cell death and suppress cell proliferation in a variety of transformed cells in culture and ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Nanostructured Calcium Phosphate for Gene Delivery to Bone

    SBC: Angstrom Medica, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Osteoporosis is a major and growing health care problem that responds inadequately to standard pharmacologic therapy. Because of its low bone mineral density, osteoporotic bone is mechanically weak and fractures more easily than normal bone. Moreover, fracture repair is compromised in osteoporotic patients. The work described in this Phase I STTR proposal aims ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  4. Amino acid derived urea based chemicals as sEH inhibitor

    SBC: Arete Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Recent findings indicate that increasing levels of epoxides of arachidonic acid (EETs) appear to be new and excellent means to treat both hypertension and vascular inflammation. We demonstrated that in vivo inhibition of soluble epoxide hydrolase resulted in higher levels of EETs and in reduction of blood pressure and inflammation in animal models. Because the ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  5. Novel epoxide hydrolase inhibitor for stroke prevention

    SBC: Arete Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): A major cause of morbidity and mortality is the progression of organ damage associated with cardiovascular diseases. For instance, the incidence of stroke and costs associated with stroke damage continues to have a devastating impact on public health despite numerous treatments aimed at cardiovascular risk factors. Recent findings indicate that increasing lev ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  6. Quantitation Pulmonary Delivery of Therapeutic Protein

    SBC: Arizeke Pharmaceuticals, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Arizeke Pharmaceuticals, Inc. is focused on the pulmonary delivery of protein therapeutics (including antibodies) to treat pulmonary disease. Arizeke's technology provides a unique ability to deliver large therapeutic proteins into the lung parenchyma and interstitium and into the lymphatic drainage system. Examples of indications that can be targeted by this t ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Radiosensitization by modulating inhibitors of apoptosis

    SBC: Ascenta Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Radioresistance markedly impairs the efficacy of tumor radiotherapy and involves anti-apoptotic signal transduction pathways that prevent radiation-induced cell death. The inhibitors of apoptosis proteins (IAP) are important intrinsic cellular inhibitors of apoptosis, highly expressed in prostate and lung cancer cells, and play an important role in resistance ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  8. AEGIS: A Pixel-array Readout IC for Gamma-ray Imaging

    SBC: Augustine Engineering            Topic: N/A

    DESCRIPTION (provided by applicant): CdZnTe arrays are promising detectors for improving nuclear medicine imaging, but existing CdZnTe cameras have limited spatial resolution and small numbers of pixels (space bandwidth product = SpBW). We show that major performance improvements will require high SpBW (>10A5) and small pixels (high resolution). The best approach to obtaining high SpBW detectors i ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  9. Design of an Automated Psoriasis Treatment System

    SBC: Boston Array Technologies, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Up to 3 percent of populations worldwide have psoriasis. A large number of the patients with psoriasis can be treated using UV light exposure. We propose to employ a light modulating microchip based on recent Micro Electro Mechanical Systems (MEMS) technological developments to build an Automated Psoriasis Treatment System. The overall goal of Phase I a ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  10. Isotopically Labeled Nucleotides for Biomolecular NMR

    SBC: CASSIA, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of the proposed research is to scale up the production and manufacture of high-value ribonucleoside triphosphates containing stable isotope labels. The use for these products is in biomolecular studies of RNA structure using Nuclear Magnetic Resonance (NMR) spectroscopy. The market for these products is structural biology groups in academic and industr ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government